Microbiology of urinary tract infections in Gaborone, Botswana

PLoS One. 2013;8(3):e57776. doi: 10.1371/journal.pone.0057776. Epub 2013 Mar 4.

Abstract

Objective: The microbiology and epidemiology of UTI pathogens are largely unknown in Botswana, a high prevalence HIV setting. Using laboratory data from the largest referral hospital and a private hospital, we describe the major pathogens causing UTI and their antimicrobial resistance patterns.

Methods: This retrospective study examined antimicrobial susceptibility data for urine samples collected at Princess Marina Hospital (PMH), Bokamoso Private Hospital (BPH), or one of their affiliated outpatient clinics. A urine sample was included in our dataset if it demonstrated pure growth of a single organism and accompanying antimicrobial susceptibility and subject demographic data were available.

Results: A total of 744 samples were included. Greater than 10% resistance was observed for amoxicillin, co-trimoxazole, amoxicillin-clavulanate, and ciprofloxacin. Resistance of E. coli isolates to ampicillin and co-trimoxazole was greater than 60% in all settings. HIV status did not significantly impact the microbiology of UTIs, but did impact antimicrobial resistance to co-trimoxazole.

Conclusions: Data suggests that antimicrobial resistance has already emerged to most oral antibiotics, making empiric management of outpatient UTIs challenging. Ampicillin, co-trimoxazole, and ciprofloxacin should not be used as empiric treatment for UTI in this context. Nitrofurantoin could be used for simple cystitis; aminoglycosides for uncomplicated UTI in inpatients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amoxicillin-Potassium Clavulanate Combination / pharmacology
  • Amoxicillin-Potassium Clavulanate Combination / therapeutic use
  • Ampicillin / pharmacology
  • Ampicillin / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Botswana / epidemiology
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use
  • Comorbidity
  • Drug Resistance, Multiple, Bacterial / drug effects
  • Female
  • Gram-Negative Bacteria / drug effects*
  • Gram-Negative Bacteria / growth & development
  • Gram-Positive Bacteria / drug effects*
  • Gram-Positive Bacteria / growth & development
  • HIV Infections / epidemiology*
  • HIV Infections / virology
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Nitrofurantoin / pharmacology
  • Nitrofurantoin / therapeutic use
  • Retrospective Studies
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Urinary Tract Infections / drug therapy*
  • Urinary Tract Infections / epidemiology*
  • Urinary Tract Infections / microbiology*

Substances

  • Anti-Bacterial Agents
  • Ciprofloxacin
  • Amoxicillin-Potassium Clavulanate Combination
  • Ampicillin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Nitrofurantoin